The Next Wave of Biosimilars
What It Means for Employers, Health Plans and Their Members
WHY YOU SHOULD WATCH
The landscape looks a lot different today than when Humira® biosimilars launched in 2023. How can payers, patients and plan sponsors benefit from this expanding market for alternatives to other biologics?
Tune into to this short webinar to learn:
- A refresher on biologics, biosimilars, and how they differ from brand and generic conventional drugs
- Approval, efficacy, safety, and importance of interchangeability
- Potential shifts in cost savings, access and market competition
- The robust 2025 launch pipeline, including Stelara® biosimilars
- Current market dynamics, formulary impact and utilization trends
Brittany Ulrich, PharmD, CSP, BCBSS, also touches on strategies that can help plans inform transitions to biosimilars, from active communication and outreach to member and provider education.
And don’t miss the Q&A with insights on copay assistance, plus PBM coverage of brand biologics and Stelara biosimilars.
MEET THE PRESENTERS
Brittany Ulrich, PharmD, CSP, BCBBS
Specialty Pharmacist, Sales
Shelby Luzenske, PharmD
WATCH ON DEMAND
Fill out the form below to gain unlimited access to the full webinar—it’s a conversation you don’t want to miss.
Product and brand names are trademarks of their respective holders. Inclusion in this material does not imply affiliation or endorsement.
